**CURRICULUM VITAE**

**Bryan P. Schneider**

Indiana University School of Medicine

Indiana University Melvin and Bren Simon Cancer Center

Indiana Cancer Pavilion, Room 473

535 Barnhill drive

Indianapolis, IN 46202

Telephone: 317-948-1186

E-mail: bpschnei@iu.edu

**EDUCATION**:

*UNDERGRADUATE*: University of Evansville, B.S. Majors: Biology & Chemistry 1995

 Summa Cum Laude graduate

*GRADUATE*: Indiana University School of Medicine, M.D. 1999

*POST DOCTORAL*: Internal Medicine Internship June 1999 – May 2000

 Indiana University, Indianapolis, IN.

 Internal Medicine Residency June 2000 – June 2001

 Indiana University, Indianapolis, IN.

 Hematology/Oncology Fellowship July 2001 – June 2005

 Indiana University, Indianapolis, IN.

**ACADEMIC APPOINTMENTS:**

***Associate Professor of Medicine*** July 2011 – Present

 Divisions of Hematology/Oncology & Clinical Pharmacology

 Indiana University School of Medicine.

***Associate Professor*** July 2011 – Present

 Department of Medical and Molecular Genetics (Secondary Appointment)

 Indiana University School of Medicine.

**HOSPITAL APPOINTMENTS:**

Indiana University Hospital, Indianapolis, Indiana

Richard L. Roudebush VA Medical Center, Indianapolis, Indiana, ***Consultant***

Eskenazi Memorial Hospital, Indianapolis, Indiana, ***Consultant***

**SPECIALTY BOARD STATUS:**

Medical Oncology, Board Certified 2004 – 2024

Internal Medicine, Board Certified 2003 – 2013

**LICENSURE AND CERTIFICATION:**

Medical Licensing Board, Indiana Health Professions Bureau

Controlled Substance Registration, Indiana Health Professions Bureau

Drug Enforcement Administration, United States Department of Justice

**PROFESSIONAL ORGANIZATIONS/LEADERSHIP:**

***Affiliate member***, Indiana University Melvin and Bren Simon Cancer Center Elected 2005

***Associate member***, American Society of Clinical Oncology (ASCO) 2005 – Present

***Member***, Hoosier Oncology Group (HOG) 2005 – Present

***Board of Directors***, Hoosier Oncology Group (HOG) 2009 – 2015

***Member***, Consortium of Breast Cancer Pharmacogenetics 2005 – 2011

***Member***, Pharmacogenetics Research Network 2005 – 2011

***Member***, Eastern Cooperative Oncology Group (ECOG) 2007 – Present

***Vice-Chair of Pharmacogenetics Sub-committee***, ECOG 2008 – Present

***Member of Developmental Therapeutics (DT) Committee***, ECOG 2009 – Present

***Chair of Education Symposium for DT Committee***, ECOG 2010

***Co-Chair of Survivorship Working Group***, ECOG 2010 – Present

***Member of Molecular Profiling Working Group***, ECOG 2010 – Present

***Member,*** Komen Scientific Advisory Council/Komen Scholars2010 – Present

***Associate Director***, Indiana Institute for Personalized Medicine 2011 – Present

***Director***, Indiana Institute for Personalized Medicine 2011 – 2015

 Craig Brater Scholar Program

***Full Member,*** Breast Cancer Program-Indiana University Simon Cancer Center 2011 – Present

***Expert Panel Member,*** American Society of Clinical Oncology (ASCO) 2012 – 2013

 “Neuropathy in Cancer Patients Guideline”

***Expert Panel Member***, American Society of Clinical Oncology (ASCO) 2012 – 2013

 “Tumor Biomarkers in Early Stage Breast Cancer Guideline”

 ***Founder and Director,*** Indiana University Health Precision Genomics Program 2014 – Present

*This clinical program was designed to help identify targeted therapies for patients with no standard options. This clinic uses targeted somatic sequencing and host genomics to select therapies with the best risk to benefit ratio.*

**PATENTS:**

International Publication Number: WO 2009/073540 A2. Published June 11, 2009

*Biomarker for bevacizumab outcome (survival and hypertension)*

Provisional Patent Application No. 61/448,593 Filed March 2, 2011

*Materials and methods for identifying patients susceptible to developing*

*bevacizumab induced hypertension*

Provisional Patent Application No. 61/436,813 Filed January 27, 2011

*Materials and methods for identifying patients susceptible to*

*developing taxane induced neuropathy*

**HONORS AND AWARDS:**

“Merit award”, American Society of Clinical Oncology (ASCO) 2002 & 2003

“MD Fellowship Award”, Eastern Cooperative Oncology Group (ECOG) 2004

 Research and Education Foundation’s Paul Carbone

 “Career Development Award”, American Society of Clinical Oncology (ASCO) 2006

Susan G. Komen for the Cure Scientific Advisory Board 2010

Shawn Hanson Breast Cancer Investigator 2011 – 2013

Highlighted in American Society of Clinical Oncology Official Press Program 2011

\*Less than one percent of Annual Meeting abstracts are chosen for this distinction

Highlighted in the Best of American Society of Clinical Oncology Program  2011

“Early Career Achievement Award”, Indiana University School of Medicine 2011

“Lifetime Achievement Award”, Susan G. Komen for the Cure 2011

“Forty under 40”, Indianapolis Business Journal 2012

“ECOG Young Investigator Award” 2012

Sheila Ward Investigator 2013

Vera Bradley Investigator 2013 – Present

“Advancements in Health Care” Finalist, Indianapolis Business Journal 2016

**TEACHING ASSIGNMENTS:**

**Oncology fellows, Indiana University, core lecture series (1-hour):**

 “Neoadjuvant Chemotherapy in Breast Cancer” 2005 – 2007

 “Challenging Cases in Breast Cancer” 2005 – 2006

 “Overview of Hormonal Therapy” 2009 – 2011

 “Board review for Breast Cancer” 2009 – 2011

**Oncology fellows, Indiana University, case conference (1-hour):** 2005 – present

 Weekly participation

**Oncology fellows, Indiana University, journal club (1 ½ hours):** 2005 – present

 Monthly participation, review of articles

**Breast Oncology multidisciplinary conference, Indiana University (1 hour):** 2005 – present

 Weekly review of cases, teaching oncology fellows, radiation oncology

 and surgical residents

**Clinical Pharmacology Fellows Core Lecture Series (1-hour):** 2007 – 2010

 Individualized Medicine for Solid Tumors”

**Hematology-Oncology Division Core Lecture Series (1-hour):** 2005 – 2009

Monthly lecture on “Breast Cancer” to Internal Medicine residents and medical students from Indiana University, as well as, pharmacy students from Indiana University, Purdue University and Butler University

**Internal Medicine Board Review Course (Medicine Residents):**

 “Internal Medicine Board Review; Oncology Section II”, Indianapolis, IN. 2007

**Fellowship Mentoring:**

Scott Herbert, MD (Hematology/Oncology Fellow) 2004 – 2007

Primary advisor

Nseobong Ntukidem, MD (Clinical Pharmacology Fellow) 2005 – 2006

Served on mentorship committee

Srikar Malireddy, MD (Clinical Pharmacology & Hematology/Oncology Fellow) 2007 – 2008

*Formal mentoring committee, assisted with the development of his abstract “A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis” which was presented at ASCO in 2007.*

Anuj Agarwala, MD (Hematology/Oncology Fellow) 2007 – 2008

Primary advisor

Jose Azar, MD (Hematology/Oncology Fellow) 2007

*Assisted in the development of his abstract which was published in the ASCO presentation proceedings “Is the blood brain barrier relevant in metastatic germ cell tumors”. I have also helped with the development of the corresponding manuscript which has recently been published.*

Abdulateef Aregbe, MD (Clinical Pharmacology Fellow) 2009 – 2011

Formal training committee member and Laboratory Advisor

Costantine Albany, MD (Hematology/Oncology Fellow) 2012

Laboratory Advisor

Tarah Ballinger, MD (Hematology/Oncology Fellow) 2016

Mentored work on conjoint-based analysis with manuscript to be submitted 2016.

*In addition to individualized mentorship, I routinely have one to two fellows that rotate through my outpatient breast cancer clinic. In this setting, I observe physical exam skills and evaluate formulation of assessment and plan for complex referral cases.*

**Internal Medicine Resident Mentoring**

Safi Shadha, MD 2007 – 2010

Primary advisor

Michael Stout, MD 2007

Translational research mentor for elective month

Mary Baker, MD 2008 – 2011

Primary advisor

Sausan Abouharb, MD 2009

Translational research mentor for elective month

Jeremy Force, DO 2012 – Present

Primary advisor

Lina Gordy, MD 2013 – Present

Primary advisor

Nawal Kassem, MD 2015 – Present

Primary mentor

**Medical Student Mentoring**

Anne Kitchens 2007 – 2008

Primary advisor

John Holden 2008 – 2009

Primary advisor

Lina Gordy 2012 – 2013

Primary advisor

Nawal Kassem 2014 – 2015

Primary advisor

**Other Student Mentoring**

Vincent Akinola (Medical School Applicant) 2005 – 2006

*Oversaw the mentorship for his laboratory training*

David Bond (Undergraduate) 2006

*IU Cancer Center Research program*

Jennifer Tornatta, RN (Nurse Practitioner Student) 2007

*Shadowed in my outpatient breast cancer clinic for a semester which served as a*

*portion of her formal training*

Maria Barragan (High School Student) 2011

*Summer research program*

Nawal Kassem (Medical Student) 2012

*Summer research program*

Courtney Glos (Medical Student) 2013

*Summer research program*

Revathi Kolipara (Medical Student) 2014

Romina Deldar (Medical Student)

*Summer research program*

Kristina Mulry (Medical Student) 2015

Victoria Longe (Undergraduate Student)

*Summer research program*

Kyle Lewellen (Medical Student) 2016

Rina Yadav (Medical Student)

Geneva Cunninggham (MD/PhD Student)

*Summer research program*

**Graduate Student Mentoring Department of Medical/Molecular Genetics**

Milan Radovich (formal graduate committee chair) 2009 – 2011

Claire Li (graduate student rotation mentor) 2010

Kelly Holohan (graduate student rotation & committee member) 2011

Jillian Koziel (graduate committee member) 2011 – Present

**PROFESSIONAL SERVICE:**

**Service to the discipline - national and international:**

American Society of Clinical Oncology (ASCO)

 Foundation International Travel Grants Program

 Junior Faculty Mentor 2005

 Discussant in Clinical Science Symposium 2009

 Discussant for Breast Cancer Session 2012

Eastern Cooperative Oncology Group (ECOG)

 Pharmacogenetics Committee Vice – Chair

 Developmental Therapeutics Core Committee Member

 Chair of Education Symposium for Developmental Therapeutics Committee

 Breast Core Committee Member

 Co-Chair of Survivorship Working Group

 Molecular Profiling Working Group member

**Ad hoc reviewer:**

 New England Journal of Medicine

 Journal of Clinical Oncology

 Clinical Cancer Research

 Archives of Medical Research

 Breast Cancer Research and Treatment

**Service to patients and community:**

Featured speaker at Camp Blue Bird, “Updates in Breast Cancer”, Indianapolis, IN. 2005

Featured speaker at Baskets by Immanuel, “An Evening to Remember – Making Cancer 2005 Therapies Better”, Indianapolis, IN.

Featured speaker for The Wellness Community, “New Discoveries in Breast Cancer”, 2005 Indianapolis, IN.

Featured speaker for Holy Angels Church, “An Update in the Treatment of Breast Cancer” 2005 Indianapolis, IN.

Featured speaker for Holy Angel’s Church, “Breast Cancer 101”, Indianapolis, IN. 2006

Featured speaker for Valley Mills Christian Church, “Updates in Clinical Oncology”, 2007 Indianapolis, IN.

Featured speaker for Breast Cancer Survivor’s Group from Terre Haute, 2011

“Personalized Medicine for Breast Cancer”, Indianapolis, IN

**UNIVERSITY SERVICE:**

Member, Scientific Review Committee for the IU Simon Cancer Center 2005 – Present

Interviewer of Internal Medicine Residency candidates 2006 – 2008

Mary Ellen’s Tissue Bank – Executive Committee & Chair of Proposal Committee 2006 – 2007

Medical Student Mentoring Program, Team B Faculty co-facilitator of quarterly 2007

 meetings with medical students

The Susan G. Komen for the Cure Tissue Bank at the IU 2007 – Present

Simon Cancer Center - Executive Committee & Chair of Proposal Committee

Cancer Quality Oversight Team, Co-Chair of Breast Cancer Division 2007 – 2008

Hoosier Oncology Group (HOG) Correlative Sciences Committee 2008 – Present

HOG Board of Directors 2009 – 2015

IU Simon Cancer Center Screen and Search Committee for Cancer Center Director 2009

IU Breast Cancer Tissue Bank Approval Committee 2009 – Present

IU School of Medicine Screen and Search Committee for Pharmacology- 2013

Toxicology Department Chair

IU Simon Cancer Center Screen and Search Committee for Basic Breast 2012 – 2013

 Cancer chair

The Susan G. Komen for the Cure Tissue Bank at the IU Simon 2013 – Present

 Cancer Center – Director of the Research Advisory Council

IU Simon Cancer Center Developmental Board-keynote speaker: October 2012

“Personalized Cancer Genomics: Clinical Implementation of a Paradigm Shift”

IU Simon Leadership Council- Keynote speaker August 2013

“Personalized Cancer Genomics: Clinical Implementation of a Paradigm Shift”

**Principal Investigator for the following clinical trials: (responsible** **for conduct of the clinical trial at Indiana University)**

**Previous:**

**Friends for Life: (2005 – 2006)**

Friends for life: This was a large recruitment effort that coincided with the 2005 and 2006 Susan G. Komen Race for the Cure in Indianapolis, IN. The goal was to collect multiple samples of blood and medical data from women with a history of breast cancer as well as healthy controls. DNA was extracted for genetic analysis and comparison between the two groups. Over 2000 samples had been generated from this effort and have now become part of The Susan G. Komen for the Cure Normal Tissue Bank at the I.U. Simon Cancer Center. Funded by Catherine Peachey Fund grant, GCRC CReFF award, and Breast Cancer Research Foundation grant.

**Premenopausal AC study: (2005 – 2009)**

Correlative trial to assess the relationship between cytochrome P450 polymorphisms and chemotherapy induced premature ovarian failure for pre-menopausal women receiving doxorubicin and cyclophosphamide. Funded by an ECOG Paul Carbone Fellowship award.

**Enzastaurin: (2007 – 2008)**

Randomized phase II trial for HER2 negative, first line metastatic breast cancer comparing a standard regimen of paclitaxel and bevacizumab with or without an experimental agent, enzastaurin. This trial was conducted through the Hoosier Oncology Group (HOG) but was closed early due to futility of the agent.

**CPTAC: (2007 – 2012)**

This project is a Hoosier Oncology Group protocol which is studying the development of several proteomic platforms for precise detection and quantification of biomarkers relevant to breast cancer. It includes the recruitment of 200 controls and 200 women undergoing treatment for breast cancer. This correlative study involves a longitudinal follow-up for those women undergoing treatment. Funded by an NIH/NCI grant.

**PTC-299: (2009 – 2011)**

Phase I/II trial combining an anti-VEGF agent (PTC 299) with an aromatase inhibitor for patients with metastatic breast cancer. This is an industry sponsored study. My laboratory is also collaborating with PTC to find biomarkers for this agent using an in vitro model system.

**E3108: (2010 – 2013)**

Co-Chair for E3108. E3108 is a Cooperative Group trial led by ECOG designed to prospectively assess the impact that CYP2D6 metabolizer status has on outcome for women with metastatic breast cancer receiving tamoxifen.

**C40503: (2010 – 2013)**

Co-Chair for C40503. This trial is a randomized phase III Cooperative Group trial (led by the CALGB) comparing first line hormonal therapy to hormonal therapy with bevacizumab for women with metastatic breast cancer.

**Active:**

**ATEMPT Trial (2013 – Present)**

Local PI and Director of correlative studies for this trial. This is a randomized Phase II study of Trastuzumab emtansine (T-DM1) vs. Paclitaxel in combination with Trastuzumab for Stage I HER2-positive breast cancer

**BRE 12-158 (2014 – Present)**

PI- This trial was investigator designed and funded internally by the Vera Bradley Foundation and the Walther Cancer Institute. This trial is a randomized phase II trial for patients with triple negative breast cancer who have residual disease after neoadjuvant therapy. Patients are randomized to standard of care vs. genomically guided therapy for 4 cycles using any FDA approved drug. The primary endpoint of this trial is 2-year disease free survival with plans to enroll 171 patients.

**OTHER PROFESSIONAL ACTIVITIES:**

**Invited and Society Lectures:**

**Hematology/Oncology Grand Rounds: (CME, 1-hour, physicians and nurses)** 2005

“From Pharmacogenetics to Friends for Life”, Indiana University Heme-Onc

Grand Rounds, Indianapolis, IN

**Consortium of Breast Cancer Pharmacogenetics (CoBRA)**

“Pharmacogenetics of breast cancer angiogenesis”, Indianapolis, IN. 2006

“Pharmacogenetics of breast cancer angiogenesis”, Indianapolis, IN. 2007

**Internal Medicine Grand Rounds (CME)**

“Pharmacogenetics of breast cancer angiogenesis”, Indianapolis, IN. 2008

**10th International Symposium on Anti-Angiogenic Agents**

“Targeted therapy for breast cancer: decoding the host hallmark”, San Diego, CA. 2008

**Joint summit regarding optimal approach to identifying genetic effects on therapeutic response: NIH/ Pharamcogenetic Research Network (PGRN)/ Cooperative Breast Cancer Groups of North America:**

“ECOG Pharmacogenomics: Anti-Angiogenic Agents”, Bethesda, MD. 2008

**Eastern Cooperative Oncology Group (ECOG)**

“VEGF Biomarker discovery”, Boston, MA. 2008

“Genome wide association studies to identify biomarkers for anti-angiogenic 2008

therapy in breast cancer”, Ft. Lauderdale, FL.

"Comprehensive Biomarker Discovery Project for Bevacizumab in Breast Cancer", 2009

Philadelphia, PA.

General Session keynote speech: “Breast Cancer Genomics and Pharmacogenomics: 2012

Making it Personal”, Ft. Lauderdale, FL.

**Research Advocacy Network (RAN)**

“Pharmacogenomics and how it is changing research”, Indianapolis, IN. 2009

“Applied Genomics- an overview of basic concepts”, Indianapolis, IN. 2009

“Pharmacogenomics and how it is changing research”, Orlando, FL. 2009

“The Komen Promise Grant: Overview and Findings” Indianapolis, IN. 2013

**Dana Farber Cancer Institute: Breast Cancer Seminar**

“Pharmacogenomics of Angiogenesis” Boston, MA. 2009

**American Society of Clinical Oncology (ASCO)**

Discussant for oral platform session-Clinical Science Symposium: Targeted Therapy in 2009 Metastatic Renal Cell Carcinoma: The Biology of Response, Resistance, and Clinical Therapeutics “Pharmacogenomics to predict toxicity of targeted therapy”. Orlando, FL.

Clinical Science Symposium Oral Presentation 2011

"Genetic associations with taxane-induced neuropathy by genome wide

association study (GWAS) in E5103". Chicago, IL.

*Highlighted in ASCO’s official Press Program. Less than 1% of abstracts are chosen for this distinction.*

Educational Symposium 2011

“Single Nucleotide Polymorphisms (SNPs) as Potential Predictive Biomarkers for VEGF-targeted Agents”. Chicago, IL.

ASCO Breast Oral Presentation: 2011

“Relationship between taxane-induced neuropathy and clinical outcomes after adjuvant chemotherapy”. San Francisco, CA.

Discussant for Breast Cancer Session 2012

“Personalized medicine for ER+ and HER2+ breast cancer” Chicago, IL.

**NCI Translational Science Meeting** 2009

“Association of genetic polymorphisms of VEGF & VEGFR-2 with outcome

in E2100”. Washington DC.

**12th International Symposium on Anti-Angiogenic Agents** 2010

**“**SNPs and Anti-VEGF Therapy”,San Diego, CA.

**Komen Scientific Advisory Council (Komen Scholars)**

“Comprehensive biomarker discovery project for bevacizumab in breast cancer”, 2011

Baltimore MD.

“Clinical Implementation of Pharmacogenetics: Biomarkers for Cancer Drug Toxicity”, 2015

Dallas, TX.

**Oncological Sciences: Cancer Prevention and Control Retreat** 2011

“Personalized Medicine for Bevacizumab: New Dimensions in Therapeutic

Individualization”, Purdue University, West Lafayette, IN.

**Cancer Center Grand Rounds: Northwestern University** 2012

“Breast Cancer Genomics and Pharmacogenomics: Making it Personal”, Chicago, IL.

**San Antonio Breast Cancer Symposium** 2012

Mini-Symposium: “Exploring germline variability as predictors for therapy-induced

toxicity”, San Antonio, TX.

**Breast Cancer Grand Rounds: Massachusetts General Hospital-Harvard** 2013

“Breast Cancer Genomics and Pharmacogenomics: Making it Personal”, Boston, MA.

**Review Courses:**

**American Society of Clinical Oncology Review (CME):**

“Overview of hormonal manipulation + a little chemo” 2006

 IU Simon Cancer Center, Indianapolis, IN

“The best of breast cancer – 2007” 2007

 Methodist Hospital network meeting, Indianapolis, IN

“ASCO 2007 – The best of metastatic breast cancer” 2007

 IU Simon Cancer Center, Indianapolis, IN

“ASCO 2010 – Highlights of metastatic breast cancer” 2010

 IU Simon Cancer Center, Indianapolis, IN

**San Antonio Breast Cancer Symposium (CME):**

“Prevention and tumor biology” 2007

 IU Simon Cancer Center, Indianapolis, IN

“Prevention and tumor biology” 2008

 IU Simon Cancer Center, Indianapolis, IN

“Angiogenesis and Breast Biology” 2009

 IU Simon Cancer Center, Indianapolis, IN

“Chemotherapy and Breast Biology” 2010

 IU Simon Cancer Center, Indianapolis, IN

“Chemotherapy and Breast Biology” 2011

 IU Simon Cancer Center, Indianapolis, IN

“Genomics and breast biology” 2013

 IU Simon Cancer Center, Indianapolis, IN

**Internal Medicine Board Review (for Residents):**

“Internal Medicine Board Review; Oncology Section II”, Indianapolis, IN 2007

**Susan G. Komen for the Cure:**

Advocates in Science Training: Dallas, TX. 2009

Komen Affiliate Meeting: “The Role of the Medical Oncologist in Granting”, 2010

Dallas, TX.

**Other:**

The Amelia Project-Giving Wings to Research: “Update of Friends for Life”, 2006

Indianapolis, IN

CME talk for visiting oncologists from Mexico: “Pharmacogenetics in 2007

breast cancer: The new age of targeting”, Indianapolis, IN

The Amelia Project-Giving Wings to Research: “Promise Grant”, Indianapolis, IN 2010

**GRANTS AND FELLOWSHIPS:**

**Previous-Other**

Eastern Cooperative Oncology Group (ECOG) Research and Education 2004-2005

Foundation’s Paul Carbone, MD Fellowship Award: $25,000

*“Cytochrome P450 Pharmacogenetics as a Predictor of Toxicity and Clinical Efficacy in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Loco-regional Breast Cancer”.*

**Role – Principal Investigator (PI).**

Catherine Peachey Fund Concept Grant recipient: 2005

 *“Pilot Evaluation of the Role of Polymorphisms in Candidate Genes on* $10,000

 *Angiogenesis and Breast Cancer”.*

**Role – Principal Investigator (PI).**

Clinical Research Feasibility Funds (CReFF) Program Grant (NIH sponsored) recipient: 2005

 *“Pilot Evaluation of the Role of Polymorphisms in Candidate Genes on* $25,200

 *Angiogenesis and Breast Cancer”.*

**Role – Principal Investigator (PI).**

**Prior-Peer Reviewed (Principal Investigator in parentheses):**

The ASCO Foundation (Schneider, BP) 1/2006 – 12/2008

1.2 Calendar $56,700

Pharmacogenetics of angiogenesis in breast cancer

*The major goal of this project is to explore the associations of polymorphisms in genes that mediate angiogenesis with the likelihood of developing breast cancer, the ultimate angiogenic phenotypes of breast cancer (prognosis), and ultimately, treatment responses.*

**Role: Principal Investigator (PI)**

W81XWH-05-1-0326 (Carpenter, J) 2/2005 – 3/2008

0.12 Calendar $100,000

Department of Defense; Army

The Role of Serotonin in Hot Flashes after Breast Cancer

*The major goal of this project is to assess the role of serotonin in hot flashes in women who have previously been diagnosed with breast cancer.*

**Role: Co-Investigator**

Showalther Trust (Schneider, BP) 7/2007 – 06/2008

0.6 Calendar $50,000

Assessment of the Role of Genetic Polymorphisms in Angiogenesis Genes on VEGFR-2 Expression, Activation and Inhibition

*The major goal of this project is to study how genetic differences within our own blood vessels may affect angiogenesis and how this might impact the effectiveness of therapy designed to block angiogenesis.*

**Role: Principal Investigator (PI)**

Genentech (Schneider, BP) 1/2007 – 12/2007

0.6 Calendar $51,685

Differential response of breast cancer patients on E2100 treated with Bevacizumab as a function of genetic polymorphisms of VEGF

*The major goal of this project is to assess for the effect of known variant polymorphisms of the VEGF gene and the KDR gene as related to outcome in breast cancer patients treated with Bevacizumab on E2100.*

**Role: Principal Investigator (PI)**

U24 CA126480 (Regnier, F) 10/2006 – 9/2011

0.6 Calendar $408,861 (to Indiana University)

NIH/NCI

APT: The Analytical Proteomics Team

*The major goal of this project is to develop platforms for precise detection and quantification of biomarkers of relevance for breast and prostate cancer.*

**Role: Co-Investigator**

RFA: IBC 10-80-10 (Schneider, BP) 12/2009 – 11/2015

Inflammatory Breast Cancer Research Foundation $50,000

Next-generation whole transcriptome sequencing in triple-negative inflammatory breast cancer to comprehensively identify novel therapeutic targets

*The goal of this project is to identify novel therapeutic targets in inflammatory breast cancer patients using next generation sequencing.*

**Role: Principal Investigator (PI)**

The Breast Cancer Intergroup (TBCI) of North America Correlative Sciences 8/2010-7/2015

Grant (Schneider, BP) $50,000

Validation of RWDD3 and candidate SNPs for taxane-induced neuropathy in E1199

 *The goal of this is to help in the validation of SNP biomarkers for taxane-induced peripheral neuropathy. This grant will help specifically to fund tissue acquisition (along with a grant from the Susan G. Komen for the cure SAC). This tissue acquisition is critical to the completion of our validation study for which the genotyping is covered by an ACRA grant from ASCO*

**Role: Principal Investigator (PI)**

The Advanced Clinical Research Award in Breast Cancer (Schneider, BP) 9/2011-8/2015

0.6 Calendar $450,000

Conquer Cancer Foundation, ASCO, and the Breast Cancer Research Foundation

Genetic Predictors of taxane induced peripheral neuropathy in E1199

*The goal of this project is to validate provocative SNP biomarkers for taxane-induced peripheral neuropathy identified by genome wide association study from E5103 in the clinical trial E1199.*

**Role: Principal Investigator (PI)**

Komen Promise Award (Schneider, BP) 5/2009-8/2014

3 Calendar $5,825,619

Susan G. Komen for the Cure Foundation

Comprehensive Biomarker Discovery Project for Bevacizumab in Breast Cancer

*The goal of this project is to identify a biomarker to predict which patients with breast cancer will be most likely to experience benefit and least likely to experience toxicity from bevacizumab in the adjuvant setting*

**Role: Principal Investigator (PI)**

R-01 CA155311-01A1 (Schneider, BP) 9/2011-7/2011

1.2 Calendar $981,429

NIH/NCI

VEGF gene amplification/deletion and haplotype as biomarkers for bevacizumab in breast cancer

*The goal of this project is to study the role of VEGF amplification/deletion (as determined by FISH) as a biomarker of outcome for patients with breast cancer treated with bevacizumab. In addition, a comprehensive SNP analysis will be carried out to further improve therapeutic individualization.*

**Role: Principal Investigator (PI)**

**Active-Peer Reviewed (Principal Investigator in parentheses):**

Komen SAC Grant-SAC110056 (Schneider, BP) 7/2010 -6/2017

0.5 Calendar $750,000

Susan G. Komen for the Cure Foundation

Validation of biomarkers for taxane induced peripheral neuropathy

*The goal of this is to help in the validation of SNP biomarkers for taxane-induced peripheral neuropathy. This grant will help specifically to fund tissue acquisition (along with a grant from the TBCI) and for supplies for this project. This tissue acquisition is critical to the completion of our validation study for which the genotyping is covered by an ACRA grant from ASCO.*

**Role: Principal Investigator (PI)**

R01CA194030-01A1 (He, C) 07/2015-06/2019

0.6 Calendar

An integrative approach to identify causal epigenetic markers for breast cancer

**Role: Co-Investigator**

**PRINT AND ELECTRONIC PUBLICATIONS:**

**Peer Reviewed Publications:**

1. 1. Franchetti, P; Cappellacci, L; Sheikha, GA; Jayaram, HN; Gurudutt, VV; Sint, T; **Schneider, BP**; Jones, WD; Goldstein, BM; Perra, G; De Montis, A; Loi, AG; La Colla, P and Grifantini, M. Synthesis, structure, and antiproliferative activity of selenophenfurin, an inosine 5'-monophosphate dehydrogenase inhibitor analogue of selenazofurin. *J Med Chem* **40**, 1731-1737 (1997).

2. Franchetti, P; Cappellacci, L; Perlini, P; Jayaram, HN; Butler, A; **Schneider, BP**; Collart, FR; Huberman, E and Grifantini, M. Isosteric analogues of nicotinamide adenine dinucleotide derived from furanfurin, thiophenfurin, and selenophenfurin as mammalian inosine monophosphate dehydrogenase (type I and II) inhibitors. *J Med Chem* **41**, 1702-1707 (1998).

3. **Schneider, BP**; Ganjoo, KN; Seitz, DE; Picus, J; Fata, F; Stoner, C; Calley, C and Loehrer, PJ. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. *Oncology* **65**, 218-223 (2003).

4. **Schneider, BP**; Kesler, KA; Brooks, JA; Yiannoutsos, C and Einhorn, LH. Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal nonseminomatous germ cell cancer. *J Clin Oncol* **22**, 1195-1200 (2004).

5. **Schneider, BP** and Miller, KD. Angiogenesis of breast cancer. *J Clin Oncol* **23**, 1782-1790 (2005).

6. **Schneider, BP**; Skaar, TC; Sledge, GW; Badve, S; Li, L and Flockhart, DA. Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. *Breast Cancer Res Treat* **96**, 209-215 (2006).

7. Stearns, V; **Schneider, BP**; Henry, NL; Hayes, DF and Flockhart, DA. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. *Nat Rev Cancer* **6**, 886-893 (2006).

8. Azar, JM; **Schneider, BP** and Einhorn, LH. Is the blood-brain barrier relevant in metastatic germ cell tumor? *Int J Radiat Oncol Biol Phys* **69**, 163-166 (2007).

9. **Schneider, BP**; Fukunaga, A; Murry, D; Yoder, C; Fife, K; Foster, A; Rosenberg, L; Kelich, S; Li, L and Sweeney, C. A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumors. *Cancer Chemother Pharmacol* **59**, 261-268 (2007).

10. **Schneider, BP** and Sledge, GW, Jr. Drug insight: VEGF as a therapeutic target for breast cancer. *Nat Clin Pract Oncol* **4**, 181-189 (2007).

11. Kesler, KA; Rieger, KM; Hammoud, ZT; Kruter, LE; Perkins, SM; Turrentine, MW; **Schneider, BP**; Einhorn, LH and Brown, JW. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. *Ann Thorac Surg* **85**, 371-378 (2008).

12. **Schneider, BP**; Radovich, M; Sledge, GW; Robarge, JD; Li, L; Storniolo, AM; Lemler, S; Nguyen, AT; Hancock, BA; Stout, M; Skaar, T and Flockhart, DA. Association of polymorphisms of angiogenesis genes with breast cancer. *Breast Cancer Res Treat* **111**, 157-163 (2008).

13. **Schneider, BP**; Wang, M; Radovich, M; Sledge, GW; Badve, S; Thor, A; Flockhart, DA; Hancock, B; Davidson, N; Gralow, J; Dickler, M; Perez, EA; Cobleigh, M; Shenkier, T; Edgerton, S; Miller, KD and Ecog. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. *J Clin Oncol* **26**, 4672-4678 (2008).

14. **Schneider, BP**; Winer, EP; Foulkes, WD; Garber, J; Perou, CM; Richardson, A; Sledge, GW and Carey, LA. Triple-negative breast cancer: risk factors to potential targets. *Clin Cancer Res* **14**, 8010-8018 (2008).

15. Carpenter, JS; Yu, M; Wu, J; Von Ah, D; Milata, J; Otte, JL; Johns, S; **Schneider, BP**; Storniolo, AM; Salomon, R; Desta, Z; Cao, D; Jin, Y; Philips, S and Skaar, TC. Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion. *Menopause* **16**, 644-652 (2009).

16. Nakshatri, H; Qi, G; You, J; Kerry, B; **Schneider, BP**; Zon, R; Buck, C; Regnier, F and Wang, M. Intrinsic subtype-associated changes in the plasma proteome in breast cancer. *Proteomics Clin Appl* **3**, 1305-1313 (2009).

17. Otte, JL; Flockhart, D; Hayes, D; Storniolo, AM; Stearns, V; **Schneider, BP**; Henry, NL; Azzouz, F; Nguyen, A; Lemler, S; Hayden, J; Jeter, S; Wright, L and Carpenter, JS. Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy. *Menopause* **16**, 653-659 (2009).

18. **Schneider, BP**; Radovich, M; Flockhart, DA; Carpenter, JS; Li, L; Robarge, JD; Storniolo, AM; Hancock, BA; Skaar, TC and Sledge, GW. Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes. *Breast Cancer Res Treat* **116**, 543-549 (2009).

19. **Schneider, BP**; Radovich, M and Miller, KD. The role of vascular endothelial growth factor genetic variability in cancer. *Clin Cancer Res* **15**, 5297-5302 (2009).

20. **Schneider, BP** and Sledge, GW, Jr. Anti-VEGF therapy as adjuvant therapy: clouds on the horizon? *Breast Cancer Res* **11**, 303 (2009).

21. Chiorean, EG; Malireddy, S; Younger, AE; Jones, DR; Waddell, MJ; Sloop, MI; Yu, M; Hall, SD; **Schneider, BP** and Sweeney, CJ. A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol* **66**, 441-448 (2010).

22. Jalal, S; Bedano, P; Einhorn, L; Bhatia, S; Ansari, R; Bechar, N; Koneru, K; Govindan, R; Wu, J; Yu, M; **Schneider, BP** and Hanna, N. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. *J Thorac Oncol* **5**, 2008-2011 (2010).

23. Komenaka, IK; Pennington, RE, Jr.; **Schneider, BP**; Hsu, CH; Norton, LE; Clare, SE; Zork, NM and Goulet, RJ, Jr. Compliance differences between patients with breast cancer in university and county hospitals. *Clin Breast Cancer* **10**, 385-391 (2010).

24. Radovich, M; Hancock, BA; Kassem, N; Mi, D; Skaar, TC and **Schneider, BP**. Resequencing of the vascular endothelial growth factor promoter reveals haplotype structure and functional diversity. *Angiogenesis* **13**, 211-218 (2010).

25. Riley, CP; Zhang, X; Nakshatri, H; **Schneider, BP**; Regnier, FE; Adamec, J and Buck, C. A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples. *J Transl Med* **9**, 80 (2011).

26. **Schneider, BP** and Sledge, GW, Jr. Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners? *J Clin Oncol* **29**, 2444-2447 (2011).

27. Wessels, AM; Flockhart, DA; Carpenter, JS; Radovich, M; Li, L; Miller, KD; Sledge, GW; Storniolo, AM; Otte, JL; Lemler, SM and **Schneider, BP**. Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving doxorubicin and cyclophosphamide. *Breast J* **17**, 536-538 (2011).

28. Holohan, KN; Lahiri, DK; **Schneider, BP**; Foroud, T and Saykin, AJ. Functional microRNAs in Alzheimer's disease and cancer: differential regulation of common mechanisms and pathways. *Front Genet* **3**, 323 (2012).

29. Jhaveri, K; Miller, K; Rosen, L; **Schneider, BP**; Chap, L; Hannah, A; Zhong, Z; Ma, W; Hudis, C and Modi, S. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. *Clin Cancer Res* **18**, 5090-5098 (2012).

30. **Schneider, BP**; Shen, F and Miller, KD. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. *Lancet Oncol* **13**, e427-436 (2012).

31. **Schneider, BP**; Zhao, F; Wang, M; Stearns, V; Martino, S; Jones, V; Perez, EA; Saphner, T; Wolff, AC; Sledge, GW, Jr.; Wood, WC; Davidson, NE and Sparano, JA. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. *J Clin Oncol* **30**, 3051-3057 (2012).

32. Slee, RB; Steiner, CM; Herbert, BS; Vance, GH; Hickey, RJ; Schwarz, T; Christan, S; Radovich, M; **Schneider, BP**; Schindelhauer, D and Grimes, BR. Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability. *Oncogene* **31**, 3244-3253 (2012).

33. Von Ah, D; Carpenter, JS; Saykin, A; Monahan, P; Wu, J; Yu, M; Rebok, G; Ball, K; **Schneider, BP**; Weaver, M; Tallman, E and Unverzagt, F. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. *Breast Cancer Res Treat* **135**, 799-809 (2012).

34. Von Ah, D; Skaar, T; Unverzagt, F; Yu, M; Wu, J; **Schneider, BP**; Storniolo, AM; Moser, L; Ryker, K; Milata, J and Carpenter, JS. Evaluating the role of serotonin on neuropsychological function after breast cancer using acute tryptophan depletion. *Biol Res Nurs* **14**, 5-15 (2012).

35. Carpenter, JS; Burns, DS; Wu, J; Otte, JL; **Schneider, BP**; Ryker, K; Tallman, E and Yu, M. Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial. *J Gen Intern Med* **28**, 193-200 (2013).

36. Juan, L; Wang, G; Radovich, M; **Schneider, BP**; Clare, SE; Wang, Y and Liu, Y. Potential roles of microRNAs in regulating long intergenic noncoding RNAs. *BMC Med Genomics* **6 Suppl 1**, S7 (2013).

37. Kitchens, JW; Kassem, N; Wood, W; Stone, TW; Isernhagen, R; Wood, E; Hancock, BA; Radovich, M; Waymire, J; Li, L and **Schneider, BP**. A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. *Clin Ophthalmol* **7**, 1987-1993 (2013).

38. **Schneider, BP**; Gray, RJ; Radovich, M; Shen, F; Vance, G; Li, L; Jiang, G; Miller, KD; Gralow, JR; Dickler, MN; Cobleigh, MA; Perez, EA; Shenkier, TN; Vang Nielsen, K; Muller, S; Thor, A; Sledge, GW, Jr.; Sparano, JA; Davidson, NE and Badve, SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. *Clin Cancer Res* **19**, 1281-1289 (2013).

39. Tevaarwerk, AJ; Gray, RJ; **Schneider, BP**; Smith, ML; Wagner, LI; Fetting, JH; Davidson, N; Goldstein, LJ; Miller, KD and Sparano, JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. *Cancer* **119**, 1140-1148 (2013).

40. Chiorean, EG; **Schneider, BP**; Akisik, FM; Perkins, SM; Anderson, S; Johnson, CS; DeWitt, J; Helft, P; Clark, R; Johnston, EL; Spittler, AJ; Deluca, J; Bu, G; Shahda, S; Loehrer, PJ; Sandrasegaran, K and Cardenes, HR. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys* **89**, 284-291 (2014).

41. Hershman, DL; Lacchetti, C; Dworkin, RH; Lavoie Smith, EM; Bleeker, J; Cavaletti, G; Chauhan, C; Gavin, P; Lavino, A; Lustberg, MB; Paice, J; **Schneider, BP**; Smith, ML; Smith, T; Terstriep, S; Wagner-Johnston, N; Bak, K; Loprinzi, CL and American Society of Clinical, O. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* **32**, 1941-1967 (2014).

42. Lai, X and **Schneider, BP**. Integrated and convenient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for LC-MS/MS analysis. *Proteomics* **14**, 2623-2627 (2014).

43. Nudelman, KN; Wang, Y; McDonald, BC; Conroy, SK; Smith, DJ; West, JD; O'Neill, DP; **Schneider, BP** and Saykin, AJ. Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. *PLoS One* **9**, e96713 (2014).

44. Radovich, M; Clare, SE; Atale, R; Pardo, I; Hancock, BA; Solzak, JP; Kassem, N; Mathieson, T; Storniolo, AM; Rufenbarger, C; Lillemoe, HA; Blosser, RJ; Choi, MR; Sauder, CA; Doxey, D; Henry, JE; Hilligoss, EE; Sakarya, O; Hyland, FC; Hickenbotham, M; Zhu, J; Glasscock, J; Badve, S; Ivan, M; Liu, Y; Sledge, GW and **Schneider, BP**. Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing. *Breast Cancer Res Treat* **143**, 57-68 (2014).

45. Ruddy, KJ; O'Neill, A; Miller, KD; **Schneider, BP**; Baker, E; Sparano, JA; Dang, C; Northfelt, DW; Sledge, GW, Jr. and Partridge, AH. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. *Breast Cancer Res Treat* **144**, 591-597 (2014).

46. **Schneider, BP**; Li, L; Shen, F; Miller, KD; Radovich, M; O'Neill, A; Gray, RJ; Lane, D; Flockhart, DA; Jiang, G; Wang, Z; Lai, D; Koller, D; Pratt, JH; Dang, CT; Northfelt, D; Perez, EA; Shenkier, T; Cobleigh, M; Smith, ML; Railey, E; Partridge, A; Gralow, J; Sparano, J; Davidson, NE; Foroud, T and Sledge, GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. *Br J Cancer* **111**, 1241-1248 (2014).

47. Hershman, DL; Loprinzi, C and **Schneider, BP**. Symptoms: Aromatase Inhibitor Induced Arthralgias. *Adv Exp Med Biol* **862**, 89-100 (2015).

48. Partridge, AH; Sepucha, K; O'Neill, A; Miller, KD; Motley, C; Swaby, RF; **Schneider, BP**; Dang, CT, Jr.; Northfelt, DW and Sledge, GW, Jr. Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer. *JAMA Oncol* **1**, 369-374 (2015).

49. Rhea, IB; Uppuluri, S; Sawada, S; **Schneider, BP** and Feigenbaum, H. Incremental prognostic value of echocardiographic strain and its association with mortality in cancer patients. *J Am Soc Echocardiogr* **28**, 667-673 (2015).

50. **Schneider, BP**; Hershman, DL and Loprinzi, C. Symptoms: Chemotherapy-Induced Peripheral Neuropathy. *Adv Exp Med Biol* **862**, 77-87 (2015).

51. **Schneider, BP**; Li, L; Radovich, M; Shen, F; Miller, KD; Flockhart, DA; Jiang, G; Vance, G; Gardner, L; Vatta, M; Bai, S; Lai, D; Koller, D; Zhao, F; O'Neill, A; Smith, ML; Railey, E; White, C; Partridge, A; Sparano, J; Davidson, NE; Foroud, T and Sledge, GW, Jr. Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. *Clin Cancer Res* **21**, 5082-5091 (2015).

52. **Schneider, BP**; O'Neill, A; Shen, F; Sledge, GW; Thor, AD; Kahanic, SP; Zander, PJ and Davidson, NE. Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). *Br J Cancer* **113**, 1651-1657 (2015).

53. Ballinger, T; Kassem, N; Shen, F; Jiang, G; Smith, M; Railey, E; Howell, J; White, C and **Schneider, BP**. Discerning the clinical relevance of biomarkers in early stage breast cancer. Submitted (2016).

54. Cheng, L; **Schneider, BP** and Li, L. A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients. *J Am Med Inform Assoc* **23**, 741-749 (2016).

55. Dickler, MN; Barry, WT; Cirrincione, CT; Ellis, MJ; Moynahan, ME; Innocenti, F; Hurria, A; Rugo, HS; Lake, DE; Hahn, O; **Schneider, BP**; Tripathy, D; Carey, LA; Winer, EP and Hudis, CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). *J Clin Oncol* **34**, 2602-2609 (2016).

56. Force, J; Saxena, R; **Schneider, BP**; Storniolo, AM; Sledge, GW, Jr.; Chalasani, N and Vuppalanchi, R. Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. *J Clin Oncol* **34**, e9-12 (2016).

57. Mosher, CE; Daily, S; Tometich, D; Matthias, MS; Outcalt, SD; Hirsh, A; Johns, SA; Rand, K; **Schneider, BP**; Mina, L; Storniolo, AM; Newton, E and Miller, K. Factors underlying metastatic breast cancer patients' perceptions of symptom importance: a qualitative analysis. *Eur J Cancer Care (Engl)* (2016).

58. Mosher, CE; Tometich, DB; Hirsh, A; Rand, KL; Johns, SA; Matthias, MS; Outcalt, SD; Bricker, J; **Schneider, BP**; Mina, L; Storniolo, AM; Newton, E and Miller, K. Symptom experiences in metastatic breast cancer patients: relationships to activity engagement, value-based living, and psychological inflexibility. *Psychooncology* (2016).

59. Nudelman, KN; McDonald, BC; Wang, Y; Smith, DJ; West, JD; O'Neill, DP; Zanville, NR; Champion, VL; **Schneider, BP** and Saykin, AJ. Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy. *J Clin Oncol* **34**, 677-683 (2016).

60. Radovich, M; Kiel, PJ; Nance, SM; Niland, EE; Parsley, ME; Ferguson, ME; Jiang, G; Ammakkanavar, NR; Einhorn, LH; Cheng, L; Nassiri, M; Davidson, DD; Rushing, DA; Loehrer, PJ; Pili, R; Hanna, N; Callaghan, JT; Skaar, TC; Helft, PR; Shahda, S; O'Neil, BH and **Schneider, BP**. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. *Oncotarget* (2016).

61. Radovich, M; Solzak, JP; Hancock, BA; Conces, ML; Atale, R; Porter, RF; Zhu, J; Glasscock, J; Kesler, KA; Badve, SS; **Schneider, BP** and Loehrer, PJ. A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. *Br J Cancer* **114**, 477-484 (2016).

62. **Schneider, BP**; Lai, D; Shen, F; Jiang, G; Radovich, M; Li, L; Gardner, L; Miller, KD; O'Neill, A; Sparano, JA; Xue, G; Foroud, T and Sledge, GW, Jr. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. *Oncotarget* **7**, 82244-82253 (2016).

63. **Schneider, BP**; Shen, F; Gardner, L; Radovich, M; Li, L; Miller, KD; Jiang, G; Lai, D; O'Neill, A; Sparano, JA; Davidson, NE; Cameron, D; Gradus-Pizlo, I; Mastouri, RA; Suter, TM; Foroud, T and Sledge, GW, Jr. Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. *Clin Cancer Res* **23**, 43-51 (2017).

64. Vaz Luis, I; O’Neill, A; Sepucha, K; Miller, KD; Baker, E; Dang, CT; Northfelt, DW; Winer, EP; Sledge, GW; **Schneider, BP**; and Partridge, A. Survival Benefit Needed to Undergo Chemotherapy: Patients’ and Physicians’ Preferences. Accepted. *Cancer* (2017).

65. **Schneider, BP**; Shen, F; Jiang, G; O'Neill, A; Radovich, M; Li, L; Gardner, L; Lai, D; Foroud, T; Sparano, J; Sledge, GW and Miller, KD. Impact of Genetically Determined Race on Outcomes in ECOG-ACRIN-E5103. Submitted (2017).

**Teaching publications:**

1. Miller K, Vaena D, **Schneider BP**, “Targets and Arrows: The Future of Breast Cancer Therapy?” Medscape Hematology-Oncology eJournal, 5(2), 2002.
2. **Schneider BP**, Vaena, D, Miller K, “Promise of Targeted New Agents in Breast Cancer.” Physician’s Education Resource, June, 4 (2): 3-7, 2002.
3. Schneider BP, Houck W, Miller K, “Targeting HER2, EGFR and VEGF in breast cancer; therapeutic potential and current status” Medscape Hematology-Oncology eJournal, 2003.
4. **Schneider BP,** Houck W, and Sledge G,“Targeted therapy in breast cancer” *Diseases of the Breast Updates*, 6 (3), 1-13, 2003.
5. Soule S, **Schneider BP**, Houck W, Sledge G, “Targeted Therapy for Breast Cancer” Advanced Therapy of Breast Disease, Second Edition, p. 830, 2004.
6. Sledge G, Miller K, **Schneider BP**, Sweeney C, “Resistance to antiangiogenic agents” Cancer Drug Resistance, Ed. B.A. Teicher. pp.391-410. Totowa, NJ: Humana Press, 2006.
7. Bedano P, **Schneider BP**, Miller K, Sledge G, “Antiangiogenic Therapy in Breast Cancer” Antiangiogenic Cancer Therapy, Eds. DW Davis, RS Herbst, JL Abbruzzese, pp. 559-585. Boca Raton: CRC Press, 2008.

**Abstracts/presentations:**

1. Franchetti, P; Cappellacci, G; Abu Sheika, G; Jayaram, H; **Schneider, BP**; Collart, F and Grifantini, M. Synthesis and IMP Dehydrogenase (Type I and Type II) Inhibitory Activity of Isosteric NAD Analogs Derived from Thiophenfurin and Furanfurin. *Nucleosides, Nucleotides and Their Biological Applications XII International Roundtable* (1996).
2. **Schneider, BP**; Ganjoo, K; Seitz, D; Picus, J; Fata, F; Stoner, C; Calley, C and Loehrer, P. Phase II study of gemcitabine and docetaxel in combination for advanced pancreatic cancer - A Hoosier Oncology Group study. *Proceedings of the American Society of Clinical Oncology* (2002) #546.
3. **Schneider, BP**; Kesler, K; Brook, J; Yiannoutsos, C and Einhorn, L. Outcome of patients with residual germ cell or non-germ cell malignancy after resection of primary mediastinal non-seminomatous germ cell cancer. *Proceedings of the American Society of Clinical Oncology* (2003) #1560.
4. Lemler, S; Rufenbarger, C; Skaar, T; Murphy, V; Rush-Taylor, A; Garvey, J; Thompson, B; Christmon, D; Coleman, N; Rosenberg, L and **Schneider, BP**. Creating a DNA bank for pharmacogenomic epidemiology; the Friends for Life study. *Breast Cancer Research and Treatment* (2005).
5. **Schneider, BP**; Skaar, T; Sledge, G; Badve, S; Li, L and Flockhart, D. Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. *Breast Cancer Research and Treatment* (2005) #1103.
6. **Schneider, BP**; Radovich, M; Flockhart, D; Carpenter, J; Li, L; Robarge, J; Storniolo, A; Lemler, S; Nguyen, A; Skaar, T and Sledge, G. Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes. *San Antonio Breast Cancer Symposium* (2006) #5084.
7. **Schneider, BP**; Radovich, M; Sledge, G; Li, L; Robarge, J; Skaar, T; Storniolo, A and Flockhart, D. Association of genetic polymorphisms of angiogenesis genes and breast cancer risk. *San Antonio Breast Cancer Symposium* (2006) #5085.
8. Azar, J; Einhorn, L and **Schneider, BP**. Is the blood-brain barrier relevant in metastatic germ cell tumors? *Proceedings of the American Society of Clinical Oncology* (2007) #15618.
9. Malireddy, S; Chiorean, E; Foster, A; Jones, D; Waddell, M; Margol, M; Hall, S; **Schneider, BP** and Sweeny, C. A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic (PK) analysis. *Proceedings of the American Society of Clinical Oncology* (2007) #14012.
10. Miller, K; Rosen, L; Modi, S; **Schneider, BP**, S; Roy, J; Chap, L; Paulsen, M; Kersey, K; A, H and Hudis, C. Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T). *Proceedings of the American Society of Clinical Oncology* (2007) #1115.
11. **Schneider, BP**; Wang, M; Radovich, M; Sledge, G; Badve, S; Thor, A; Flockhart, D; Hancock, B; Davidson, N and Miller, K. Association of genetic polymorphisms of VEGF and VEGFR-2 with outcome in E2100. *San Antonio Breast Cancer Symposium* (2007).
12. Taraska, A; Borges, S; Radovich, M; Philips, S; Nguyen, A; Li, L; Robarge, J; Lemler, S; **Schneider, BP**; Flockhart, D and Skaar, T. Effect of CYP2D6 genotype on antidepressant use patterns. *Clinical Pharmacology & Therapeutics* (2007).
13. Bedano, P; Perkins, S; Burns, M; Kessler, K; Nelson, R; **Schneider, BP**; Risley, L; Dropcho, S and Loehrer, P. A phase II trial of erlotinib blus bevacizumab in patients with recurrent thymoma or thymic carcinoma. *Proceedings of the American Society of Clinical Oncology* (2008) #19087.
14. Carpenter, J; Skaar, T; **Schneider, BP**; Storniolo, A; Wu, J; Yu, M and Milata, J. The Role of Serotonin in Hot Flashes After Breast Cancer. *Era of Hope Conference* (2008).
15. Hancock, B; Radovich, M; Badve, S; Thorat, M; Azzouz, F and **Schneider, BP**; Association of Single Nucleotide Polymorphisms in Angiogenesis Genes with Expression of VEGF and VEGFR-2 in Breast Carcinoma. *American Association for Cancer Research* (2008) #288.
16. **Schneider, BP**; Karwal, M; Laufman, L; Sylvester, L; Taylor, M; Sidor, C; Hannah, A; Arnott and Miller, K. A phase II study of oral MKC-1 for metastatic breast cancer (MBC). *Proceedings of the American Society of Clinical Oncology* (2008) #1046.
17. Hancock, B; Radovich, M; Kassem, N; Mi, D; Skaar, T and **Schneider, BP**. Resequencing of the Vascular Endothelial Growth Factor promoter reveals haplotype structure and functional diversity. *San Antonio Breast Cancer Symposium* (2009) #2122.
18. Miller, K; Christmon, D; Perkins, S; Sun, J; **Schneider, BP**; Storniolo, A; Clare, S; Ozerdem, U and Sledge, G. A pilot study of vascular endothelial growth factor inhibition with bevacizumab in patients with lymphedema following breast cancer treatment. *Proceedings of the American Society of Clinical Oncology* (2009) #9523.
19. Miller, K; Estes, M; Perkins, S; **Schneider, BP**; Matei, D; Storniolo, A; Ingram, D; Yoder, M; Kern, K and Sledge, G. An Exploratory Study of the Biological Activity of Sunitinib as a Component of Neoadjuvant Therapy for Breast Cancer. *San Antonio Breast Cancer Symposium* (2009) #202.
20. Radovich, M; Clare, S; Pardo, I; Hancock, B; Sledge, G; Rufenbarger, C; Storniolo, A; Mathieson, T; Sun, J; Henry, J; Hilligoss, E; Elliott, J; Richt, R; Hickenbotham, M; Glasscock, J; Liu, Y and **Schneider, BP**. Next-Generation Whole Transcriptome Sequencing of Triple-Negative Breast Tumors and Normal Tissues. *San Antonio Breast Cancer* *Symposium* (2009) #6134.
21. Anderson, S; Cardenes, H; Akisik, F; Johnston, E; Clark, R; Perkins, S; Johnson, C; Loehrer, P; **Schneider, BP** and Chiorean, E. Phase I study of sorafenib (S) with gemcitabine (G)-based radiotherapy (G-RT) in patients (pts) with locally advanced pancreatic adenocarcinoma (LAUPC). *Proceedings of the American Society of Clinical Oncology* (2010) #4139.
22. Miller, K; Brown, C; Perksin, S; **Schneider, BP**; Storniolo, A and Sledge, G. A Pilot Study of Vascular Endothelial Growth Factor Inhibition with Pazpanib in Patients with Lymphedema Following Breast Cancer Treatment. *San Antonio Breast Cancer Symposium* (2010) #14-02.
23. Radovich, M; Clare, S; Sledge, G; Pardo, I; Mathieson, T; Kassem, N; Hancock, B; Storniolo, A; Rufenbarger, C; Lillemoe, H; Sun, J; Henry, J; Goulet, R; Hilligoss, E; Siddiqui, A; Breu, H; Sakarya, O; Hyland, F; Muller, M; Popescu, L; Zhu, J; Hickenbotham, M; Glasscock, J; Ivan, M; Liu, Y and **Schneider, BP**. Decoding the Transcriptional Landscape of Triple-Negative Breast Cancer Using Next-Generation Whole Transcriptome Sequencing. *San Antonio Breast Cancer Symposium* (2010) #PD 01-08.
24. Tiersten, A; **Schneider, BP**; Dickler, M; Volm, M; Speyer, J; Novik, Y; Lehman, R; Callahan, L; Darby, C; Miller, L and Miao, H. Administration of the Novel Antiangiogenic PTC299 in Combination with Aromatase Inhibitors is Feasible and Shows Antitumor Activity in Metastatic Breast Cancer. *San Antonio Breast Cancer Symposium* (2010) #16-08.
25. Tiersten, A; Volm, M; Speyer, J; Novik, Y; Lehman, R; **Schneider, BP**; Dickler, M; Callahan, L; Darby, C; Miller, L and Miao, H. The novel antiangiogenic PTC299, as a treatment for women with metastatic breast cancer. *Proceedings of the American Society of Clinical Oncology* (2010) #e13537.
26. Dickler, M; **Schneider, BP**; Volm, M; Speyer, J; Novik, Y; Callahan, L; Darby, C; Barth, J; Ogden, A and Tiersten, A. Reduction of Circulating Serum VEGF and IL-6 Levels in Patients with Metastatic Breast Cancer: Preliminary Results of a Phase 1b Study of PTC229, an Oral Inhibitor of Tumor VEGF Expression, and Aromatase Inhibitors. *Proceedings of the American Society of Clinical Oncology* (2011) #1100.
27. Miller, K; Perkins, S; Badve, S; Sledge, G and **Schneider, BP**; PARP Inhibition after Preoperative Chemotherapy in Patients with Triple-Negative Breast Cancer (TNBC) or Known BRCA 1/2 Mutations: Hoosier Oncology Group BRE09-146. *San Antonio Breast Cancer Symposium* (2011) #OT3-01-05.
28. **Schneider, BP**; Li, L; Miller, K; Flockhart, D; Radovich, M; Hancock, B; Kassem, N; Foroud, T; Koller, D; Badve, S; Li, Z; Partridge, A; O'Neill, A; Sparano, J; Dang, C; Northfelt, D; Smith, M; Railey, E and Sledge, G. Genetic associations with taxane-induced neuropathy by genome wide association study (GWAS) in E5103. *Proceedings of the American Society of Clinical Oncology* (2011) #1000.
29. Tevaarwerk, A; Gray, R; **Schneider, BP**; Smith, M; Wagner, L; Miller, K and Sparano, J. Survival in Metastatic Breast Cancer (MBC): No Evidence for Improved Survival Following Distant Recurrence after Adjuvant Chemotherapy. *San Antonio Breast Cancer Symposium* (2011) #PD 08-01.
30. Partridge, A; Sepucha, K; O'Neill, A; Miller, K; Motley, C; Swaby, R; **Schneider, BP**; Dang, C; Northfelt, D and Sledge, G. Does unblinding of treatment assignment impact participant perceptions in clinical trials? *Proceedings of the American Society of Clinical Oncology* (2012) #6025.
31. Porter, R; Radovich, M; Rojas, L; Suleiman, Y; Conces, M; Shirar, K; Nelson, R; Spittler, A; Burns, M; Kesler, K; Badve, S; **Schneider, BP** and Loehrer, P. Factors influencing outcome of thymic epithelial tumors (TET). *Proceedings of the American Society of Clinical Oncology* (2012) #7108.
32. Radovich, M; Atale, R; Clare, S; Sledge, G and **Schneider, BP**. Next-Generation RNA Sequencing of Triple Negative Breast Cancer Compared to Donated Microdissected Normal Epithelium and Adjacent Normal Tissues. *San Antonio Breast Cancer Symposium* (2012) #PD 01-08.
33. Radovich, M; Porter, R; Conces, M; Suleiman, Y; Badve, S; Kesler, K; **Schneider, BP** and Loehrer, P. Next-generation sequencing of thymic malignancies. *Proceedings of the American Society of Clinical Oncology* (2012) #7032.
34. **Schneider, BP**; Wang, M; Stearns, V; Martino, S; Jones, V; Perez, E; Saphner, T; Wolff, A; Sledge, G; Wood, W; Davidson, N and Sparano, J. Relationship between taxane-induced neuropathy and clinical outcomes after adjuvant chemotherapy. *American Society of Clinical Oncology Breast Cancer Symposium* (2012) #270.
35. Suleiman, Y; Radovich, M; Rojas, L; Porter, R; Conces, M; Shirar, K; Nelson, R; Spittler, A; Siddiqui, B; Burns, M; Badve, S and **Schneider, BP**. Factors affecting survival of patients with Masaoka stage IV thymic epithelial tumors (TET). *Proceedings of the American Society of Clinical Oncology* (2012) #7107.
36. Lin, N; Gelman, R; Younger, W; Sohl, J; Freedman, R; Sorensen, A; Bullitt, E; Harris, G; Morganstern, D; **Schneider, BP**; Krop, I and Winer, E. Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM). *Proceedings of the American Society of Clinical Oncology* (2013) #513.
37. Partridge, A; Sepucha, K; O'Neill, A; Miller, K; Baker, E; Dang, C; Northfelt, D; Sledge, G and **Schneider, BP**. Does biomarker information impact patients' preferences for therapy? *Proceedings of the American Society of Clinical Oncology* (2013) #6527.
38. Ruddy, K; O'Neill, A; Miller, K; **Schneider, BP**; Baker, E; Sparano, J; Dang, C; Northfelt, D and Sledge, G. Biomarker prediction of chemotherapy-related amenorrhea. *Proceedings of the American Society of Clinical Oncology* (2013) #9508.
39. Metzger-Filho, O; Lin, N; Come, S; Openshaw, T; **Schneider, BP**; Giobbie-Hurder, A; Burstein, H and Mayer, E. A phase II study of eribulin in patients with HER2-negative, metastatic breast cancer: Evaluation of efficacy, toxicity, and patient-reported outcomes. *Proceedings of the American Society of Clinical Oncology* (2014) #TPS1138.
40. Nudelman, K; Wang, Y; McDonald, B; Conroy, S; Smith, D; West, J; O'Neill, D; Zanville, N; Champion, V; **Schneider, BP** and Saykin, A. Nervous system sequelae of chemotherapy treatment: Associations and proposed mechanisms. *Proceedings of the American Society of Clinical Oncology* (2014) #9652.
41. Radovich, M; Hancock, B; Solzak, J; Atale, R; Badve, S; Miller, K and **Schneider, BP**. RNA-sequencing of residual triple-negative breast cancers after neoadjuvant chemotherapy compared to matched pretreatment biopsies from the Hoosier Oncology Group trial BRE09-146. *Proceedings of the American Society of Clinical Oncology* (2014) #1002.
42. Ammakkanavar, N; Kiel, P; Nilan, E; Ferguson, M; Nance, S; Radovich, M; Helft, P and **Schneider, BP**. Feasibility of tumor genome sequencing: single center experience. *Proceedings of the American Society of Clinical Oncology* (2015) #e22131.
43. Dickler, M; Barry, W; Cirrincione, C; Ellis, M; Moynahan, M; Innocenti, F; Hurria, A; Rugo, H; Lake, D; Hahn, O; **Schneider, BP**; Tripathy, D; Winer, E and Hudis, C. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). *Proceedings of the American Society of Clinical Oncology* (2015) #501.
44. Radovich, M; Kiel, P; Nance, S; Nilan, E; Loesch, D; Penny, R and **Schneider, BP**. Integrated DNA and RNA next-generation sequencing to enable clinically actionable insights: A precision genomics clinic experience. *Proceedings of the American Society of Clinical Oncology* (2015) #e22076.
45. Gardner, L; Shen, F; Radovich, M; Li, L; Miller, K; Jiang, G; Lai, D; O'Neill, A; Sparano, J; Davidson, N; Cameron, D; Gradus-Pizlo, I; Mastouri, R; Suter, T; Foroud, T; Sledge, G and **Schneider, BP**. Genome Wide Association Study for Anthracycline-Induced Congestive Heart Failure. *Proceedings of the American Society of Clinical Oncology* (2016) #1017.
46. Innocenti, F; Owzar, K; Jiang, C; Sibley, A; Mulkey, F; Carey, L; Tripathy, D; **Schneider, BP**; Barry, W; Winer, E; Hudis, C; McLeod, H and Dickler, M. A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozol (L) with or without bevacizumab (B) in CALGB 40503. *Proceedings of the American Society of Clinical Oncology* (2016) #538.
47. Li, D; Dickler, M; McCall, L; Hahn, O; Hudia, C; Cohen, H; Muss, H; Ballman, K; Winer, E; Tripathy, D and **Schneider, BP**. Identifying risk factors for toxicity in patients (pts) with hormone-receptor positive (HR+) advanced breast cancer treated with bevacizumab, plus letrozole: A CALGB 40503 (Alliance) correlative study. *Proceedings of the American Society of Clinical Oncology* (2016) #10047.
48. **Schneider, BP**. Impact of genetically determined race on outcomes in E5103. *AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved* (2016) Oral Presentation.
49. **Schneider, BP**; Lai, D; Shen, F; Jiang, G; Radovich, M; Li, L; Gardner, L; Miller, K; O'Neill, A; Sparano, J; Xue, G; Foroud, T and Sledge, G. Charcot-Marie Tooth Gene, SBF2, Associated with Taxane-Induced Peripheral Neuropathy in African Americans. *Proceedings of the American Society of Clinical Oncology* (2016) #1026.
50. Stearns, V; O'Neill, A; **Schneider, BP**; Flockhart, D; Skaar, T; Liu, M; Lohrisch, C; Goetz, M; Sologuren, C; Sparano, J; Villa, D; Silverman, P; Cheeman, P; Moore, D and Sledge, G. A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108. *Proceedings of the American Society of Clinical Oncology* (2016) #546.